# Lung Cancer, Non-Small Cell FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/lung-cancer-non-small-cell

> No upcoming FDA catalysts in lung Cancer, Non-Small Cell; 5 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for lung Cancer, Non-Small Cell?

No upcoming FDA catalysts in lung Cancer, Non-Small Cell; 5 past events are recorded. Press release filed with the SEC (EX-99): "Top-line data expected in Q4 2026 o JADE - pivotal Phase 3 - dostarlimab monotherapy versus placebo in locally advanced unresected head and neck squamous cell carcinoma (PD-L1 hiPghD-L1 CPS≥1) post chemoradiation" [Calendar and source filings](https://sec-api.dev/indications/lung-cancer-non-small-cell)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-088239, https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/lung-cancer-non-small-cell#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 5, 2025 | [Cobolimab primary completion](https://sec-api.dev/pdufa/cobolimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT04655976 (Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04655976)) |
| June 30, 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT06472076 (A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06472076)) |
| July 1, 2026 | [Cobolimab topline data readout](https://sec-api.dev/pdufa/cobolimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT04655976 (Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04655976?tab=results)) |
| October 26, 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT05565378 (A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05565378)) |
| Oct 2026 to Jan 2027 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Lung Cancer, Non-Small Cell | scheduled | "Top-line data expected in Q4 2026 o JADE - pivotal Phase 3 - dostarlimab monotherapy versus placebo in locally advanced unresected head and neck squamous cell carcinoma (PD-L1 hiPghD-L1 CPS≥1) post chemoradiation" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm)) |

## Drugs

- [Cobolimab](https://sec-api.dev/pdufa/cobolimab) (GSK)
- [Jemperli (dostarlimab)](https://sec-api.dev/pdufa/dostarlimab) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/lung-cancer-non-small-cell.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lung Cancer, Non-Small Cell FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/lung-cancer-non-small-cell

```bibtex
@misc{secapidev_indications_lung_cancer_non_small_cell_20261116,
  title        = {Lung Cancer, Non-Small Cell FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/lung-cancer-non-small-cell}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_lung_cancer_non_small_cell_20261116","title":"Lung Cancer, Non-Small Cell FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/lung-cancer-non-small-cell","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
